Recruitment

Recruitment Status
Completed
Estimated Enrollment
92

Exclusion Criterias

Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation
Presence of cirrhosis
...
Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation
Presence of cirrhosis
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Chronic use of systemic immunosuppressive agents
Co-infection with HIV or hepatitis B virus (HBV)
Pregnant or nursing female or male with pregnant female partner

Summary

Conditions
Hepatitis C Virus Infection
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Exclusion Criterias

Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation
Presence of cirrhosis
...
Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation
Presence of cirrhosis
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Chronic use of systemic immunosuppressive agents
Co-infection with HIV or hepatitis B virus (HBV)
Pregnant or nursing female or male with pregnant female partner

Locations

San Antonio, Texas
Marlton, New Jersey
Orlando, Florida
Saint Louis, Missouri
Philadelphia, Pennsylvania
...
San Antonio, Texas
Marlton, New Jersey
Orlando, Florida
Saint Louis, Missouri
Philadelphia, Pennsylvania
San Juan
Berlin, New Jersey
Costa Mesa, California
Kansas City, Missouri
DeLand, Florida
Knoxville, Tennessee

Tracking Information

NCT #
NCT02185794
Collaborators
Not Provided
Investigators
Study Director: Gilead Study Director Gilead Sciences